Comparison of the potentiation of specific tumor immunity in mice by Corynebacterium parvum or BCG.
Two independent studies have compared killed C. parvum (CP) vaccine with viable BCG (Pasteur) and BCG (Glaxo) vaccines, respectively, for potentiation of antitumor immunity when injected with irradiated tumor cells into B6D2F1 AND CBA-T6T6 mice. Both studies concurred that, for a given number of irradiated tumor cells, larger amounts (dry weight equivalent) of BCG than CP were required to produce similar degrees of tumor immunity. Evidence also showed that stronger and more protracted immunity was mediated by CP than by BCG.
D000818:Animals; D001500:BCG Vaccine; D006084:Graft Rejection; D007109:Immunity; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D011425:Propionibacterium acnes / Q000276:immunology*; D012513:Sarcoma, Experimental / Q000276:immunology*
D001500:BCG Vaccine